Spyre Therapeutics (NASDAQ: SYRE) will participate in two June 2026 healthcare investor conferences. Management joins the Jefferies Global Healthcare Conference in New York on June 3, 2026 at 12:15 pm ET and the Goldman Sachs 47th Annual Global Healthcare Conference in Miami on June 8, 2026 at 10:00 am ET. Live audio webcasts, replays, and one-on-one investor meetings are planned.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – SYRE
-1.55%
1 alert
-1.55%Session close to close
$6.40BMarket Cap
2.00KVolume
In the May 27 session, SYRE declined 1.55%, reflecting a mild negative market reaction.
This announcement highlights Spyre’s upcoming presence at the Jefferies Global Healthcare Conference...
Analysis
This announcement highlights Spyre’s upcoming presence at the Jefferies Global Healthcare Conference on June 3, 2026 and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026, with fireside chats and one-on-one meetings. In context, the company recently completed sizable equity offerings under an effective S-3 shelf for up to $500,000,000 and reported robust cash resources and active clinical development. Investors may watch for new disclosures or commentary emerging from these conference appearances.
Announcement of proposed public offering of common stock.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent equity offerings, typically dilutive events, were followed by positive price reactions, while operational and routine news had more modest, directionally mixed impacts.
Recent Company History
Over the last few months, Spyre reported Q1 2026 results with positive SPY001 data and strong cash resources on May 5, which coincided with a 2.72% gain. In April, the company announced and then priced and closed sizable equity offerings (proposed on April 13, priced on April 14, closed on April 16), each followed by gains between 1.17% and 7.78%. A small inducement grant on May 1 saw a marginal negative move. Today’s conference-participation news fits into an ongoing cycle of active capital markets and clinical communication.
"to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases"
Inflammatory bowel disease is a group of long‑lasting conditions that cause repeated inflammation of the digestive tract, leading to symptoms like belly pain, diarrhea, bleeding and weight loss. For investors it matters because IBD drives steady demand for medications, ongoing clinical trials, medical devices and diagnostics; think of it as a chronic maintenance market where successful treatments can create predictable, long‑term revenue streams and regulatory milestones can move stock prices.
rheumatic diseasesmedical
"standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases"
Rheumatic diseases are a group of conditions that cause chronic inflammation, pain, stiffness, or damage in joints, muscles, and connective tissues—think of the body’s hinges and supporting ropes becoming swollen or worn. For investors, they matter because treatments, long-term care needs, and prevalence influence demand for drugs, medical devices, and services; successful therapies can change a company’s sales outlook much like a new engine changing a car’s performance.
long-acting antibodiesmedical
"a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations"
Long-acting antibodies are lab-made immune proteins designed to remain active in the body much longer than standard antibodies, so they provide extended protection or treatment with fewer doses. For investors this matters because longer duration can increase patient convenience, reduce healthcare costs, and create commercial advantages—similar to a rechargeable battery that needs charging far less often—affecting market size, pricing, and adoption of a therapeutic.
WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases, today announced that management will participate in the following upcoming investor conferences:
Event: Jefferies Global Healthcare Conference – New York Date: Wednesday, June 3, 2026 Fireside Time: 12:15 pm ET
Event: Goldman Sachs 47th Annual Global Healthcare Conference – Miami Date: Monday, June 8, 2026 Fireside Time: 10:00 am ET
Members of the Spyre management team will also host one-on-one investor meetings during the conferences.
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, visit Spyre's website at www.spyre.com.
For Investors: Eric McIntyre, Spyre Therapeutics SVP of Finance and Investor Relations Eric.mcintyre@spyre.com
FAQ
When will Spyre Therapeutics (NASDAQ: SYRE) present at the Jefferies Global Healthcare Conference in June 2026?
Spyre Therapeutics presents a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 12:15 pm ET. According to Spyre Therapeutics, the session will be available via live audio webcast with replay on its investor events website.
What are the details of Spyre Therapeutics’ appearance at the Goldman Sachs Global Healthcare Conference 2026?
Spyre Therapeutics will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 10:00 am ET. According to Spyre Therapeutics, the event in Miami will feature a fireside chat and will be webcast with replay access.
How can investors access the Spyre Therapeutics (SYRE) June 2026 conference webcasts?
Investors can access live audio webcasts and replays of Spyre Therapeutics’ June 2026 conference appearances through its investor events website. According to Spyre Therapeutics, all links will be hosted at https://ir.spyre.com/events-and-presentations for convenient on-demand viewing.
Will Spyre Therapeutics management hold one-on-one investor meetings at the June 2026 conferences?
Yes, Spyre Therapeutics management plans to host one-on-one investor meetings during both June 2026 conferences. According to Spyre Therapeutics, these meetings will occur alongside the Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference appearances, offering additional engagement opportunities.
Why is Spyre Therapeutics participating in June 2026 healthcare investor conferences?
Spyre Therapeutics is joining June 2026 investor conferences to engage with the healthcare investment community. According to Spyre Therapeutics, management will present its clinical-stage focus on long-acting antibodies for inflammatory bowel and rheumatic diseases and meet investors through fireside chats and one-on-one meetings.
